Upstream Bio (UPB) EBITDA Margin (2023 - 2025)
Historic EBITDA Margin for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to 5539.39%.
- Upstream Bio's EBITDA Margin fell 24268600.0% to 5539.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 5020.08%, marking a year-over-year decrease of 20397400.0%. This contributed to the annual value of 3281.18% for FY2024, which is 15957200.0% down from last year.
- According to the latest figures from Q3 2025, Upstream Bio's EBITDA Margin is 5539.39%, which was down 24268600.0% from 4732.87% recorded in Q2 2025.
- Upstream Bio's EBITDA Margin's 5-year high stood at 1511.43% during Q3 2023, with a 5-year trough of 5656.01% in Q1 2025.
- Over the past 3 years, Upstream Bio's median EBITDA Margin value was 3439.22% (recorded in 2024), while the average stood at 3757.22%.
- In the last 5 years, Upstream Bio's EBITDA Margin crashed by -11088700bps in 2024 and then tumbled by -33102300bps in 2025.
- Over the past 3 years, Upstream Bio's EBITDA Margin (Quarter) stood at 3184.44% in 2023, then crashed by -35bps to 4293.31% in 2024, then decreased by -29bps to 5539.39% in 2025.
- Its EBITDA Margin stands at 5539.39% for Q3 2025, versus 4732.87% for Q2 2025 and 5656.01% for Q1 2025.